Annotation Detail for DGKH
Basic Information
Top
| Pathway ID | Pathway Name |
|---|
| hsa00561 | Glycerolipid metabolism |
| hsa00564 | Glycerophospholipid metabolism |
| hsa01100 | Metabolic pathways |
| hsa04070 | Phosphatidylinositol signaling system |
| Pathway ID | Pathway Name |
|---|
| Signaling by GPCR |
| Hemostasis |
| Desease Name |
|---|
| bipolar disorder |
| height |
| PSYCH |
| DEVELOPMENTAL |
| Desease Name |
|---|
| Height |
| Bipolar disorder |
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| D016572 |
Cyclosporine |
Cyclosporine results in increased expression of DGKH mRNA | increases expression | 20106945
|
| C006253 |
pirinixic acid |
[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of DGKH mRNA | affects binding|increases activity|increases expression | 19710929
|
| C006253 |
pirinixic acid |
pirinixic acid results in increased expression of DGKH mRNA | increases expression | 18301758
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D055371 |
Acute Lung Injury |
|
pirinixic acid |
3.72 | 18653653 |
| MESH:D018248 |
Adenoma, Liver Cell |
|
pirinixic acid |
4.37 | 16434500 |
| MESH:D001778 |
Blood Coagulation Disorders |
|
pirinixic acid |
3.70 | 19483382 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
2.85 | 12371664 |
| MESH:D002779 |
Cholestasis |
|
Cyclosporine |
8.98 | 19486331 |
| MESH:D002779 |
Cholestasis |
|
pirinixic acid |
8.98 | 19176532 |
| MESH:D003876 |
Dermatitis, Atopic |
|
pirinixic acid |
2.61 | 18249437 |
| MESH:D004487 |
Edema |
|
pirinixic acid |
3.02 | 12083418 |
| MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
9.44 | 19224547 |
| MESH:D005234 |
Fatty Liver |
|
pirinixic acid |
9.44 | 19236843 20131406 |
| MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.90 | 12639820 12168785 |
| MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
5.11 | 8708960 |
| MESH:D006333 |
Heart Failure |
|
pirinixic acid |
2.81 | 20558911 |
| MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
5.31 | 15720958 |
| MESH:D006529 |
Hepatomegaly |
|
pirinixic acid |
3.76 | 18467677 19176532 16221962 19772884 |
| MESH:D006943 |
Hyperglycemia |
|
pirinixic acid |
3.69 | 20558911 |
| MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.24 | 10903974 |
| MESH:D007333 |
Insulin Resistance |
|
pirinixic acid |
2.93 | 16306350 |
| MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
5.51 | 15604871 |
| MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.58 | 8314463 10903974 18776723 |
| MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
3.17 | 12371664 |
| MESH:D008106 |
Liver Cirrhosis, Experimental |
|
pirinixic acid |
1.35 | 15474484 |
| MESH:D008113 |
Liver Neoplasms |
|
pirinixic acid |
1.95 | 20007298 16377806 15890375 |
| MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.86 | 16801185 |
| MESH:D009135 |
Muscular Diseases |
|
pirinixic acid |
4.27 | 16239165 |
| MESH:D009203 |
Myocardial Infarction |
|
pirinixic acid |
2.30 | 19151258 |
| MESH:D015428 |
Myocardial Reperfusion Injury |
|
pirinixic acid |
3.33 | 16411023 |
| MESH:D009369 |
Neoplasms |
|
pirinixic acid |
2.14 | 17405874 |
| MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
5.51 | 17954296 |
| MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.75 | 19348381 18481113 |
| MESH:D009765 |
Obesity |
|
pirinixic acid |
1.90 | 20558911 |
| MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.69 | 12371664 |
| MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.35 | 16882103 |
| MESH:D015427 |
Reperfusion Injury |
|
pirinixic acid |
2.58 | 19058328 |
| MESH:D014605 |
Uveitis |
|
Cyclosporine |
5.05 | 1336536 |
| MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
5.51 | 17120751 |
PharmGKB Accession:PA27315
| Releated disease ID |
Related disease Name |
| PA447199 | Bipolar Disorder |
Drug Bank